共 77 条
[1]
D'Amico E(2019)Review: patient-reported outcomes in multiple sclerosis care Mult Scler Relat Disord 33 61-66
[2]
Haase R(2017)Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials Neurotherapeutics 14 934-944
[3]
Ziemssen T(2020)Establishing a common metric for patient-reported outcomes in cancer patients: Linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) J Patient Rep Outcomes 4 106-1208
[4]
Nowinski CJ(2022)Predictors of cladribine effectiveness and safety in multiple sclerosis: A real-world, multicenter, 2-year follow-up study Neurol Ther 11 1193-268
[5]
Miller DM(2022)Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres Mult Scler 28 257-372
[6]
Cella D(2022)Real-world evidence for cladribine tablets in multiple sclerosis: Further insights into efficacy and safety Wien Med Wochenschr 172 365-613
[7]
Lee MK(2004)Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 12-365
[8]
Schalet BD(2017)Measuring treatment satisfaction in MS: Is the treatment satisfaction questionnaire for medication fit for purpose? Mult Scler 23 604-1035
[9]
Cella D(1993)The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 353-730
[10]
Yost KJ(2012)Work productivity in relapsing multiple sclerosis: Associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life Value Health 15 1029-2147